The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

A thiol-modified hyaluronan, wherein the thiol-modified hyaluronan comprises a plurality of modification groups with a thiol-group in the hyaluronan side-chains, wherein the modification group comprises an amino acid residue with basic side chain and a conjugated terminal naturally occurring amino-thiol as well as a sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of the thiol-modified hyaluronan and uses of the composition.

The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.

Provided are an injectable intraocular microgel and an injectable intraocular hydrogel that are safe to a human body and that can release a drug in the eye for a long period of time. This injectable intraocular microgel may have a form in which a drug is loaded on a hyaluronic acid microgel generated by causing hyaluronic acid copolymers to cross-link with each other through a w/o emulsion method.

The present invention relates to the manufacture of a photo-crosslinkable biodegradable tissue adhesive using a multinetwork-forming copolymer, and provides a hyaluronic acid copolymer compound having excellent elongation, mechanical properties, and tissue adhesion. The compound fundamentally does not undergo phase separation, and enables the manufacture of a tissue adhesive with desired adhesive characteristics and physical characteristics.

The present invention relates to a hyperbranched polyglycerol polyglycidyl ether having a molecular weight from 750 to 15.000 Da; and an epoxy equivalent weight from 183 to 7.000 g/eq. It also relates to a crosslinked polysaccharide obtainable by crosslinking the polysaccharide with the hyperbranched polyglycerol polyglycidyl ether. The present invention also relates to processes for their preparation and their uses in therapy, cosmetic, agriculture and food field.

A macromolecular hyaluronic acid is used as a raw material, and is subjected to production processes such as hyaluronidase hydrolysis, heating and inactivation, activated carbon filtration, and spray and dry to obtain an ultra-low molecular weight hyaluronic acid product having an average molecular weight of less than 1200 Da. The product is a mixture of hyaluronic acid disaccharide to dodecaose. The content of hyaluronic acid disaccharide is 5-40%. The content of hyaluronic acid tetrasaccharide is 40-70%. The content of hyaluronic acid hexasaccharide is 10-30%. The content of hyaluronic acid octasaccharide is 1-15%. The content of hyaluronic acid decaose is 1-10%. The content of that higher than hyaluronic acid decaose is less than 6%. Compared with other available low molecular hyaluronic acid, the product has a more significant permeation, moisturizing, and repair promotion capability, and can be widely used in fields of medical products, health care products, cosmetics and the like.

Materials and methods for preparing a hydrogel are disclosed. Specifically, two separate solutions A and B, of which the solution A comprises enzyme horseradish peroxidase and the solution B comprises hydrogen peroxide is provided. At least one of solution A or B comprises calcium ions in the form of a pharmaceutically acceptable salt, and further the solution A and/or the solution B comprises hydroxyphenyl derivative of hyaluronan of a particular formula. A hydrogel based on hydroxyphenyl derivative of hyaluronan and a method of preparing and using the same is also disclosed.